Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies

Trial details

Who runs it

Institute of Hematology & Blood Diseases Hospital, China

Trial code

NCT04993885

Record updated

24 February 2025

Original description

This prospective, open-label, single-center, one-arm clinical trial aims at evaluating the efficacy and safety of avatrombopag in Chinese adult Immune Thrombocytopenia (ITP) patients with autoantibodies fail (due to intolerance or resistance) to eltrombopag or herombopag treatment.Read full original descriptionShow less

Efficacy and Safety of Avatrombopag in the Treatment of Adult Immune Thrombocytopenia With Autoantibodies Fail to Eltrombopag or Herombopag Treatment: a Single-center, Prospective, One-arm Clinical Trial

This prospective, open-label, single-center, one-arm clinical trial aims at evaluating the efficacy and safety of avatrombopag in Chinese adult Immune Thrombocytopenia (ITP) patients with autoantibodies fail (due to intolerance or resistance) to eltrombopag or herombopag treatment.

Inclusion: The patients have provided written informed consent prior to enrollment; Men and women greater than or equal to 18 years of age; Diagnosed as ITP secondary to connective tissue diseases (including but not limited to systemic lupus erythematosus, Sjogren's syndrome and rheumatoid arthritis), primary ITP with positive antinuclear antibody but not up to the diagnostic criteria of connective tissue diseases, primary Evans syndrome, Evans syndrome secondary to connective tissue diseases, and primary ITP with positive Coomb's test but not up to the diagnostic criteria of Evans syndrome; Platelet count<30 ×10\^9/L at screening; Patients who have previously failed to receive Eltrombopag or Herombopag [poor efficacy (Eltrombopag 75 mg/d or Herombopag 7.5 mg/D, at least 4 weeks), or the efficacy cannot be maintained], or who have contraindications, can not tolerate or refuse Eltrombopag or Herombopag treatment; Treatment for ITP (including but not limited to glucocorticoids, recombinant human thrombopoietin, and other thrombopoietin receptor agonists other than Avatrombopag) must be completed before enrollment, or the dose must be stable or in a phase of reduction within 2 weeks before enrollment; Effective contraceptive measures will be taken during the clinical trial.

Exclusion: Patients with any prior history of arterial or venous thrombosis within 3 months, and with any of the following risk factors: cancer, Factor V Leiden, ATIII deficiency, or patients who are using anticoagulants or antiplatelet drugs at the beginning of screening; Those who had received rituximab within 3 months; Patients who had failed to respond to the previous use of Avatrombopag (40mg once a day for more than 4 weeks); Patients who had received splenectomy within 3 months or have splenectomy plan within 3 months; There are surgical planners during the study; Patients that had participated in other experimental researches within one month before enrollment; Patients with active thyroid disease requiring treatment; Subjects known to be allergic to Avatrombopag or any of its excipients; Patients with infectious fever (including but not limited to pulmonary infection) within 1 month or with active infection during screening; Existing hepatitis B virus, hepatitis C virus replication or HIV infection; Patients with severe cardiac or pulmonary dysfunction; History of psychiatric disorder; Patients with a history of drug/alcohol abuse (within 2 years before the study); Severe liver dysfunction (alanine aminotransferase or glutamic oxaloacetic transaminase > 3×ULN); Severe renal damage (creatinine clearance < 30 ml/min); Patients with lupus encephalopathy or lupus nephritis; Patients with cataract; Pregnant or lactating women or those planning to be pregnant during the trial; Any other circumstances that the investigator considers that the patient is not suitable to participate in the trial.

ClinicalTrials.gov NCT04993885